Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818284 | 0.98 | MEN1 (0.36) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL25862811 | 0.94 | ALDH1A1 (0.34) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL7171314 | 0.94 | NPC1 (0.32) | NPC1MTORRAB9ATSHR | |
| SCHEMBL22518978 | 0.92 | TSHR (0.33) | MEN1POLBMAPTKMT2ANPC1 | |
| SCHEMBL3413093 | 0.89 | TSHR (0.35) | NPC1MTORRAB9ATSHR | |
| SCHEMBL24308962 | 0.87 | TSHR (0.36) | NPC1MTORRAB9ATSHR | |
| SCHEMBL23572529 | 0.87 | TSHR (0.36) | NPC1MTORRAB9ATSHR | |
| SCHEMBL11373490 | 0.85 | NPC1 (0.39) | ALDH1A1NPC1MTORRAB9A | |
| SCHEMBL9553343 | 0.82 | CYP1A2 (0.33) | — | |
| SCHEMBL10479691 | 0.81 | CYP1A2 (0.44) | MEN1MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125974-A1 | PROCESS FOR MANUFACTURING AN AQUEOUS HYDROGEN PEROXIDE SOLUTION BY USING ALKYL-CYCLOHEXANE CARBONITRILE SOLVENTS | SOLVAY SA (BE) | 2024-06-20 | — | — | WO | disclosed |
| CN-107779202-B | Preparation method of negative liquid crystal compound | 河北迈尔斯通电子材料有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| CN-109370609-A | A kind of VA-LCD liquid-crystal composition of Low threshold low-power consumption low viscosity quick response | 河北迈尔斯通电子材料有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-107779203-A | A kind of VA LCD liquid-crystal compositions of Low threshold low-power consumption | 河北迈尔斯通电子材料有限公司 | 2018-03-09 | — | — | CN | disclosed |
| CN-107779202-A | A kind of preparation method of negative liquid crystal compound | 河北迈尔斯通电子材料有限公司 | 2018-03-09 | — | — | CN | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| CN-107298980-A | A kind of negative liquid crystal compound and preparation method thereof | 河北迈尔斯通电子材料有限公司 | 2017-10-27 | — | — | CN | disclosed |
| EP-1976513-B1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2015-05-07 | — | — | US | disclosed |
| US-8877975-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1976513-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | Sepracor, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007081857-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-0034415-B1 | 1-(CYCLOHEXYL OR CYCLOHEXENYL)-4-ARYL-4-PIPERIDINECARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-05-30 | — | — | EP | disclosed |
| US-4369184-A | ANTIHISTAMINES; HETEROCYCLIC NITRILES | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-18 | — | — | US | disclosed |
| EP-0034415-A1 | 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | MEN1 4234/4885POLB 2628/4885MAPT 969/4885 |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | MEN1 4234/4885POLB 2628/4885MAPT 969/4885 |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | MEN1 4234/4885POLB 2628/4885MAPT 969/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | MEN1 4234/4885POLB 2628/4885MAPT 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.